Marzia Del Re

Marzia Del Re

UNVERIFIED PROFILE

Are you Marzia Del Re?   Register this Author

Register author
Marzia Del Re

Marzia Del Re

Publications by authors named "Marzia Del Re"

Are you Marzia Del Re?   Register this Author

60Publications

1032Reads

5Profile Views

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report.

BMC Cancer 2019 Apr 30;19(1):410. Epub 2019 Apr 30.

Unit of Respiratory Medicine, Department of Critical Area and Surgical, Medical and Molecular Pathology, University Hospital of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5604-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492432PMC
April 2019

Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors.

Cancer Treat Rev 2019 Mar 19;74:21-28. Epub 2019 Jan 19.

Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2019.01.006DOI Listing
March 2019

The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer.

Pharmacogenomics 2019 Jan 6;20(1):49-68. Epub 2018 Dec 6.

Unit of Clinical Pharmacology & Pharmacogenetics, Department of Clinical & Experimental Medicine, University of Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0149DOI Listing
January 2019

Radiomics and liquid biopsy in oncology: the holons of systems medicine.

Insights Imaging 2018 Dec 14;9(6):915-924. Epub 2018 Nov 14.

Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13244-018-0657-7
Publisher Site
http://dx.doi.org/10.1007/s13244-018-0657-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269342PMC
December 2018

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.

Br J Cancer 2018 Nov 6;119(10):1252-1258. Epub 2018 Nov 6.

Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-018-0238-z
Publisher Site
http://dx.doi.org/10.1038/s41416-018-0238-zDOI Listing
November 2018

[Biosimilars in oncology. Focus on SB3 studies.]

Recenti Prog Med 2018 Nov;109(11):531-539

Dipartimento di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova - Dipartimento di Medicina Interna, DIMI, Università di Genova.

View Article

Download full-text PDF

Source
http://www.recentiprogressi.it/articoli.php?archivio=yes&
Publisher Site
http://dx.doi.org/10.1701/3031.30290DOI Listing
November 2018

Clinical pharmacology of intravitreal anti-VEGF drugs.

Eye (Lond) 2018 06 5;32(6):1010-1020. Epub 2018 Feb 5.

Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41433-018-0021-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997665PMC
June 2018

EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance.

Pharmacogenomics 2018 06 22;19(8):727-740. Epub 2018 May 22.

Clinical Pharmacology & Pharmacogenetics Unit, Department of Clinical & Experimental Medicine, University of Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0038DOI Listing
June 2018

Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells.

Stem Cells 2018 05 5;36(5):633-640. Epub 2018 Feb 5.

Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/stem.2787DOI Listing
May 2018

Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.

Crit Rev Oncol Hematol 2018 May 6;125:51-59. Epub 2018 Mar 6.

Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2018.03.002DOI Listing
May 2018

Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase.

Curr Pharm Des 2017 ;23(14):2028-2034

Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612823666170125155530DOI Listing
April 2018

Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.

Cancer Chemother Pharmacol 2018 04 23;81(4):745-754. Epub 2018 Feb 23.

Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, 55, Via Roma, 56126, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3543-6DOI Listing
April 2018

Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment.

Stem Cells Transl Med 2018 Mar 8;7(3):305-314. Epub 2018 Feb 8.

Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/sctm.17-0175DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827745PMC
March 2018

Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

Oncotarget 2018 01 21;9(5):6630-6643. Epub 2017 Dec 21.

Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.23553DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814239PMC
January 2018

Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.

Clin Lung Cancer 2017 11 18;18(6):692-697. Epub 2017 May 18.

Clinical Pharmacology and Pharmacogenetic Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.04.013DOI Listing
November 2017

Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer.

Sci Rep 2017 08 11;7(1):7931. Epub 2017 Aug 11.

Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-017-08297-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554237PMC
August 2017

Should CYP2D6 be genotyped when treating with tamoxifen?

Pharmacogenomics 2017 Jun 8;18(8):755-756. Epub 2017 Jun 8.

Clinical Pharmacology & Pharmacogenetics Unit, Department of Clinical & Experimental Medicine, University of Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2017-0065DOI Listing
June 2017

Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life.

Best Pract Res Clin Endocrinol Metab 2017 06 15;31(3):319-334. Epub 2017 Jun 15.

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S1521690X173007
Publisher Site
http://dx.doi.org/10.1016/j.beem.2017.06.001DOI Listing
June 2017

Determinants of bone specific metastasis in prostate cancer.

Crit Rev Oncol Hematol 2017 Apr 16;112:59-66. Epub 2017 Feb 16.

Medical Oncology Department, Campus Bio-Medico University, Via Alvaro del Portillo 200, 00128 Rome, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2017.02.013DOI Listing
April 2017

The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.

Cancer Treat Rev 2017 Apr 9;55:71-82. Epub 2017 Mar 9.

Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.03.001DOI Listing
April 2017

Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment.

EPMA J 2017 Mar 7;8(1):69-73. Epub 2017 Mar 7.

Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, 55, Via Roma, 56126 Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13167-017-0080-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471801PMC
March 2017

Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.

Int J Mol Sci 2017 Jan 6;18(1). Epub 2017 Jan 6.

Clinical Pharmacology and Pharmacogenetic Unit, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, 56126 Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms18010104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297738PMC
January 2017

Should CYP2D6 be genotyped when treating with tamoxifen?

Pharmacogenomics 2016 12 24;17(18):1967-1969. Epub 2016 Nov 24.

Clinical Pharmacology & Pharmacogenetics Unit, Department of Clinical & Experimental Medicine, University of Pisa, 55 Via Roma, 56126 Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2016-0162DOI Listing
December 2016

Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant.

Pharmacogenomics 2016 14;17(1):5-9. Epub 2015 Dec 14.

Departmental Unit of Medical Oncology, IRCCS Fondazione Maugeri, 4, Via Salvatore Maugeri, I-27100 Pavia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.15.146DOI Listing
September 2016

Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications.

Epigenomics 2016 08 1;8(8):1151-67. Epub 2016 Aug 1.

Department of Clinical & Experimental Medicine, University of Pisa, Via Roma 55, 56126 Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/epi.16.10DOI Listing
August 2016

Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.

World J Gastroenterol 2016 Jul;22(27):6287-95

Amalia Azzariti, Letizia Porcelli, Michele Signorile, Anna Elisa Quatrale, Clinical and Preclinical Pharmacology Laboratory, National Cancer Research Centre Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v22.i27.6287DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4945987PMC
July 2016

Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials.

Crit Rev Oncol Hematol 2016 May 27;101:12-20. Epub 2016 Feb 27.

Unit of molecular therapy and pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy; Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2016.02.013DOI Listing
May 2016

Crizotinib Resensitization by Compound Mutation.

N Engl J Med 2016 05;374(18):1790

University Hospital of Parma, Parma, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1601366DOI Listing
May 2016

Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs.

Expert Opin Drug Metab Toxicol 2015 3;11(8):1253-67. Epub 2015 Jun 3.

University of Pisa, Department of Clinical and Experimental Medicine, Via Roma 55, 56126 Pisa , Italy +39 050 2218755 ; +39 050 2218758 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425255.2015.1053460DOI Listing
March 2016

Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer.

J Theor Biol 2016 Jan 6;389:263-73. Epub 2015 Nov 6.

Clinical Pharmacology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtbi.2015.10.019DOI Listing
January 2016

Pathophysiology and pharmacological targets of VEGF in diabetic macular edema.

Pharmacol Res 2016 Jan 1;103:149-57. Epub 2015 Dec 1.

Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2015.11.003DOI Listing
January 2016

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.

Transl Lung Cancer Res 2015 Oct;4(5):584-97

1 Medical Oncology Unit, University Hospital of Parma, Parma, Italy ; 2 Department of Clinical and Experimental Medicine, Clinical Pharmacology Unit, University of Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.08.09DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630520PMC
October 2015

Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer.

Expert Opin Investig Drugs 2015 Jun 7;24(6):809-24. Epub 2015 Mar 7.

Polytechnic University of the Marche Region, Medical Oncology, AOU Ospedali Riuniti , via Conca 71, 60126 Ancona , Italy +39 0715964263 ; +39 0715964269 ;

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/13543784.2015.10
Publisher Site
http://dx.doi.org/10.1517/13543784.2015.1020370DOI Listing
June 2015

Genetic variation: effect on prostate cancer.

Biochim Biophys Acta 2014 Dec 6;1846(2):446-56. Epub 2014 Sep 6.

Department of Clinical and Experimental Medicine, University of Pisa, Italy.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0304419X140008
Publisher Site
http://dx.doi.org/10.1016/j.bbcan.2014.08.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260983PMC
December 2014

Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature.

Endocr Pract 2013 Nov-Dec;19(6):1043-9

Department of Clinical and Experimental Medicine, Section of Endocrinology, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4158/EP13093.RADOI Listing
July 2014

Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.

Expert Rev Mol Diagn 2014 May 11;14(4):453-68. Epub 2014 Apr 11.

Department of Clinical and Experimental Medicine, Clinical Pharmacology Unit, Pisa University, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737159.2014.908120DOI Listing
May 2014

DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.

Pharmacogenomics 2013 Aug;14(11):1255-72

Dipartimento di Scienze del Farmaco & Centro di Ricerca Interdipartimentale di Farmacogenetica e Farmacogenomica-CRIFF, Università del Piemonte Orientale "A. Avogadro", Largo Donegani 2, 28100 Novara, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.13.116DOI Listing
August 2013

Author's reply: To PMID 22443211.

Expert Opin Ther Targets 2013 Apr;17(4):474-5

View Article

Download full-text PDF

Source
April 2013

Pharmacogenetics of anti-estrogen treatment of breast cancer.

Cancer Treat Rev 2012 Aug 13;38(5):442-50. Epub 2011 Sep 13.

Division of Pharmacology, Department of Internal Medicine, University of Pisa, Italy.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S030573721100178
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2011.08.003DOI Listing
August 2012

Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.

Expert Opin Ther Targets 2012 Apr 23;16 Suppl 2:S111-7. Epub 2012 Mar 23.

Cancer Institute Giovanni Paolo II, Medical and Experimental Oncology Unit, Viale Orazio Flacco, 65, 70124 Bari, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.2011.652089DOI Listing
April 2012

Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.

Curr Drug Metab 2011 Dec;12(10):932-43

Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma 55, 56126 Pisa, Italy.

View Article

Download full-text PDF

Source
December 2011

Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?

EPMA J 2010 Sep 25;1(3):495-502. Epub 2010 Jul 25.

Division of Pharmacology, Department of Internal Medicine, University of Pisa, 55, Via Roma, 56126 Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13167-010-0041-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405332PMC
September 2010